Carolyn F. Orr

Carolyn F. Orr

Auto-generated profile, based on publicly available information

Carolyn F. Orr

Royal Perth Hospital

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2005 in Brain
Verified
Journal Article
Open access
PDF file
COCarolyn F. Orr
Carolyn F. Orr
DRDominic Rowe
Dominic Rowe
YMYoshikuni Mizuno
Yoshikuni Mizuno
HMHideo Mori
Hideo Mori
GHGlenda M. Halliday
Glenda M. Halliday
The pathogenesis of idiopathic Parkinson's disease is unknown, but nigral degeneration and depigmentation are associated with microglial inflammation and anti-inflammatory medications appear to protect against the disease. The possibility that humoral immunity may play a role in initiating or regulating the inflammation has been suggested by experimental studies triggering dopamine cell death using a variety of transfer strategies and the observation of CD8+ T lymphocytes and complement in the nigra in Parkinson's disease. We analysed the association between degeneration and humoral immune markers in brain tissue of patients with idiopathic (n = 13) or genetic (n = 2 with α-synuclein and n = 1 with parkin mutations) Parkinson's disease and controls without neurological disease (n = 12) to determine the humoral immune involvement in Parkinson's disease. Formalin-fixed tissue samples from the substantia nigra and primary visual cortex for comparison were stained for α-synuclein, major histocompatibility complex II (HLA), immunoglobulin M (IgM), immunoglobulin G (IgG), IgG subclasses 1–4 and IgG receptors FcγR I–III. Antigen retrieval and both single immunoperoxidase and double immunofluorescence procedures were employed to determine the cell types involved and their pattern and semiquantitative densities. Significant dopamine neuron loss occurred in all patients with Parkinson's disease, negatively correlating with disease duration (r = −0.76, P = 0.002). Although all patients had increased inflammatory HLA immunopositive microglia, the degree of inflammation was similar throughout the disease (r = 0.08, P = 0.82). All patients with Parkinson's disease had IgG binding on dopamine neurons but not IgM binding. Lewy bodies were strongly immunolabelled with IgG. A mean 30 ± 12% of dopamine nigral neurons were immunoreactive for IgG in Parkinson's disease with the proportion of IgG immunopositive neurons negatively correlating with the degree of cell loss in the substantia nigra (r = −0.67, P < 0.0001) and positively correlating with the number of HLA immunopositive microglia (r = 0.51, P = 0.01). Most neuronal IgG was the IgG1 subclass with some IgG3 and less IgG2 also found in the damaged substantia nigra. The high affinity activating IgG receptor, FcγRI, was expressed on nearby activated microglia. The low affinity activating IgG receptor, FcγRIII was expressed on cells morphologically resembling lymphocytes, whereas immunoreactivity for the inhibitory IgG receptor FcγRII was absent in all cases. This pattern of humoral immune reactivity is consistent with an immune activation of microglia leading to the targeting of dopamine nigral neurons for destruction in both idiopathic and genetic cases of Parkinson's disease.

1 December 2002 in Progress in Neurobiology
Verified
Journal Article
Closed access
COC.F Orr
C.F Orr
DRDominic Rowe
Dominic Rowe
GHG.M Halliday
G.M Halliday

1 December 2009 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
DDDennis W. Dickson
Dennis W. Dickson
HFHiroshige Fujishiro
Hiroshige Fujishiro
COCarolyn Orr
Carolyn Orr
ADAnthony DelleDonne
Anthony DelleDonne
KJKeith A. Josephs
Keith A. Josephs
JAJ. Eric Ahlskog
J. Eric Ahlskog

27 August 2013 in Neurology
Verified
Journal Article
Closed access
PDF file
BBBrendon P. Boot
Brendon P. Boot
COCarolyn F. Orr
Carolyn F. Orr
JAJ. Eric Ahlskog
J. Eric Ahlskog
TFTanis J. Ferman
Tanis J. Ferman
RRRosebud Roberts
Rosebud Roberts
BBBradley F. Boeve
Bradley F. Boeve
Objective: To determine the risk factors associated with dementia with Lewy bodies (DLB). Methods: We identified 147 subjects with DLB and sampled 2 sex- and age-matched cognitively normal control subjects for each case. We also identified an unmatched comparison group of 236 subjects with Alzheimer disease (AD). We evaluated 19 candidate risk factors in the study cohort. Results: Compared with controls, subjects with DLB were more likely to have a history of anxiety (odds ratio; 95% confidence interval) (7.4; 3.5–16; p < 0.0001), depression (6.0; 3.7–9.5; p < 0.0001), stroke (2.8; 1.3–6.3; p = 0.01), a family history of Parkinson disease (PD) (4.6; 2.5–8.6; p < 0.0001), and carry APOE ε4 alleles (2.2; 1.5–3.3; p < 0.0001), but less likely to have had cancer (0.44; 0.27–0.70; p = 0.0006) or use caffeine (0.29; 0.14–0.57; p < 0.0001) with a similar trend for alcohol (0.65; 0.42–1.0; p = 0.0501). Compared with subjects with AD, subjects with DLB were younger (72.5 vs 74.9 years, p = 0.021) and more likely to be male (odds ratio; 95% confidence interval) (5.3; 3.3–8.5; p < 0.0001), have a history of depression (4.3; 2.4–7.5; p < 0.0001), be more educated (2.5; 1.1–5.6; p = 0.031), have a positive family history of PD (5.0; 2.4–10; p < 0.0001), have no APOE ε4 alleles (0.61; 0.40–0.93; p = 0.02), and to have had an oophorectomy before age 45 years (7.6; 1.5–39; p = 0.015). Conclusion: DLB risk factors are an amalgam of those for AD and PD. Smoking and education, which have opposing risk effects on AD and PD, are not risk factors for DLB; however, depression and low caffeine intake, both risk factors for AD and PD, increase risk of DLB more strongly than in either.

1 March 2017 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
SGS.Mojtaba Golzan
S.Mojtaba Golzan
KGKathryn Goozee
Kathryn Goozee
DGDana Georgevsky
Dana Georgevsky
AAAlberto Avolio
Alberto Avolio
PCPratishtha Chatterjee
Pratishtha Chatterjee
SGStuart L. Graham
Stuart L. Graham
Retinal imaging may serve as an alternative approach to monitor brain pathology in Alzheimer’s disease (AD). In this study, we investigated the association between retinal vascular and structural changes and cerebral amyloid-β (Aβ) plaque load in an elderly cohort. We studied a total of 101 participants, including 73 elderly subjects (79 ± 5 years, 22 male) with no clinical diagnosis of AD but reporting some subjective memory change and an additional 28 subjects (70 ± 9 years, 16 male) with clinically established AD. Following a complete dilated ocular examination, the amplitude of retinal vascular pulsations and dynamic response, retinal nerve fibre layer thickness and retinal ganglion cell layer (RGCL) thickness were determined in all patients. Systemic blood pressure and carotid-to-femoral pulse wave velocity were measured. The elderly cohort also underwent magnetic resonance imaging and 18F-florbetaben (FBB)-positron emission tomographic amyloid imaging to measure neocortical Aβ standardised uptake value ratio (SUVR), and this was used to characterise a ‘preclinical’ group (SUVR >1.4). The mean FBB neocortical SUVR was 1.35 ± 0.3. The amplitude of retinal venous pulsations correlated negatively with the neocortical Aβ scores (p < 0.001), whereas the amplitude of retinal arterial pulsations correlated positively with neocortical Aβ scores (p < 0.01). RGCL thickness was significantly lower in the clinical AD group (p < 0.05). The correlation between retinal vascular changes and Aβ plaque load supports the possibility of a vascular component to AD. Dynamic retinal vascular parameters may provide an additional inexpensive tool to aid in the preclinical assessment of AD.

1 June 2009 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
COCarolyn F. Orr
Carolyn F. Orr
JAJ. Eric Ahlskog
J. Eric Ahlskog
Amiodarone hydrochloride is a class III antiarrhythmic drug prescribed commonly for atrial fibrillation and ventricular arrhythmias. It has several clinically important toxic effects, including pneumonitis, hepatotoxicity, thyroid dysfunction, and corneal microdeposits with visual disturbances.1-3 The initial experience with this drug also suggested substantial potential for neurologic toxic effects, with frequencies in these early reports ranging from 27.5% to as high as 74%1,2,4-6; the most common of these neurologic adverse effects have been tremor, ataxia, and peripheral neuropathy. However, various other neurologic adverse effects have also been reported, including cognitive impairment/encephalopathy,4,6,7 parkinsonism,8,9 optic neuropathy,10 and myopathy.6,11 On the other hand, the frequency of neurologic adverse effects in longer-term amiodarone clinical trials has been much lower, at less than 5%.12-15